Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol Meeting Abstract
| Authors: | Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; Shulman, L.; Obadi, O.; Acosta, J.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Tan, C.; Shah, U.; Lesokhin, A.; Lahoud, O.; Scordo, M.; Chung, D.; Landau, H.; Giralt, S. |
| Abstract Title: | Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol |
| Meeting Title: | 18th International Myeloma Workshop (IMW) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-10-01 |
| Start Page: | S158 |
| End Page: | S159 |
| Language: | English |
| ACCESSION: | WOS:000717640800270 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)02343-0 |
| Notes: | Meeting Abstract: P-216 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
